Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences Inc (NASDAQ:XBIOGet Free Report) was the target of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 2,200 shares, a decrease of 74.7% from the February 29th total of 8,700 shares. Based on an average daily trading volume, of 5,300 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.2% of the company’s stock are short sold.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Susquehanna International Group LLP boosted its holdings in shares of Xenetic Biosciences Inc (NASDAQ:XBIOFree Report) by 210.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,819 shares of the company’s stock after buying an additional 52,779 shares during the period. Susquehanna International Group LLP owned approximately 0.51% of Xenetic Biosciences worth $32,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 15.12% of the stock is currently owned by institutional investors.

Xenetic Biosciences Price Performance

Shares of NASDAQ XBIO opened at $3.95 on Thursday. The stock has a market capitalization of $6.08 million, a P/E ratio of -1.44 and a beta of 2.61. Xenetic Biosciences has a 1-year low of $2.55 and a 1-year high of $5.97. The business has a fifty day moving average price of $3.85 and a 200 day moving average price of $3.83.

About Xenetic Biosciences

(Get Free Report)

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.

Read More

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.